On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked
- PMID: 37525416
- DOI: 10.1080/02791072.2023.2242358
On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked
Abstract
Despite the recent and sharp rise in psychedelic research, few studies have investigated how classic psychedelic use relates to employees' work-related outcomes. This is surprising given that the increased use, decriminalization, and legalization of classic psychedelics in the United States (U.S.) has the potential to impact both employees and their organizations. Addressing this gap, the current study explores how employees' lifetime psilocybin use relates to the amount of overtime they work, thereby offering insight into what current trends in psilocybin use could mean for businesses. Using pooled, cross-sectional data from the National Survey on Drug Use and Health (2002-2014) on 217,963 adults employed in the U.S. full-time, this study tests whether lifetime psilocybin use is associated with employees' number of overtime hours worked in the past week. After adjusting for sociodemographics and other substance use, a significant negative association is found between employees' lifetime psilocybin use and the amount of overtime they reported working. Specifically, the findings suggest that lifetime psilocybin use in the U.S. full-time working population is associated with an estimated 44,348,400 fewer overtime hours worked per year and may help explain recent findings linking employees' lifetime psilocybin use to a reduction in sick leave taken.
Keywords: Psychedelics; employee; mushrooms; overtime work; psilocybin.
Similar articles
-
Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.Int J Environ Res Public Health. 2022 Sep 9;19(18):11353. doi: 10.3390/ijerph191811353. Int J Environ Res Public Health. 2022. PMID: 36141631 Free PMC article.
-
Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.J Psychopharmacol. 2022 Jan;36(1):66-73. doi: 10.1177/02698811211058933. J Psychopharmacol. 2022. PMID: 35090364
-
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.J Psychopharmacol. 2022 Jan;36(1):46-56. doi: 10.1177/02698811211058923. Epub 2022 Jan 5. J Psychopharmacol. 2022. PMID: 34983249
-
The Therapeutic Potential of Psilocybin.Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948. Molecules. 2021. PMID: 34063505 Free PMC article. Review.
-
Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.J Psychoactive Drugs. 2024 Sep-Oct;56(4):513-529. doi: 10.1080/02791072.2023.2251133. Epub 2023 Aug 24. J Psychoactive Drugs. 2024. PMID: 37615379 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous